Human CD19 Targeted T Cells Injection(CD19 CAR-T) Therapy for Relapsed and Refractory CD19-positive Lymphoma.
Status:
Recruiting
Trial end date:
2023-10-01
Target enrollment:
Participant gender:
Summary
To evaluate the safety and tolerance of human CD19 targeted T Cells injection for the
treatment of relapsed and refractory CD19-positive diffuse large B-cell lymphoma and
follicular lymphoma. Patients will be given a conditioning chemotherapy regimen of
fludarabine and cyclophosphamide followed by a single infusion of CD19 CAR+ T cells.